In this issue:
Rituximab for systemic sclerosis
Mavrilimumab in patients with severe COVID-19
Biologic or targeted synthetic DMARDs and COVID-19
Brodalumab for axial SpA
Biologic switching in juvenile idiopathic arthritis
Anterior uveitis in axial SpA with TNF or IL-17A inhibitors
Methotrexate, sulfasalazine, hydroxychloroquine vs TNF inhibitor/methotrexate in RA
Cost-effectiveness of drug monitoring-guided adalimumab in rheumatic diseases
Please login below to download this issue (PDF)